Visiopharm
- Company typePrivate
- Founded2002
- HeadquartersHørsholm, Denmark
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
Visiopharm firmographics
Firmographics- Name
- Visiopharm
- Legal name
- Visiopharm A/S
- Website
- https://visiopharm.com
- Company type
- Private
- Founded year
- 2002
- Operating status
- Acquired
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Visiopharm industry classification
Industry- Product category
- Digital Pathology Software
- NAICS
- Medical Equipment and Supplies Manufacturing (3391), Scientific Research and Development Services (5417)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826), Services-Health Services (8000)
- akta.pro primary industry
- SaMD – Imaging & Signal Analysis (AI/ML) (HLACANAG)
- akta.pro secondary industries
- Medical Imaging AI (HDAAAEAH), AI Orchestration & Imaging Analytics Platforms (Model Management/Triage) (HLACALAG), SaMD – Digital Biomarkers & Algorithmic Endpoints (HLACANAF)
Keywords
Where Visiopharm is headquartered
LocationHeadquarters
- HQ city
- Hørsholm
- HQ country
- Denmark
- HQ region
- Europe
Offices5 records
Markets served
Visiopharm business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure
Revenue model
- Software Licenses: Sale of pathology image analysis software for research and diagnostic applications. Products include Discovery, Phenoplex, and diagnostic APPs.
- Software Maintenance Service: Subscription-based software maintenance providing access to latest product versions, bug fixes, compatibility updates, and unlimited technical support. Protects software investment and ensures access to newest features.
- Professional Services: Application support hours sold as 4 or 8 hour Professional Online Support packages including guidance for image analysis, technical advice, workflow optimization, and custom project consulting.
- Training Services: Academy training programs and product training services for customers to learn how to use Visiopharm software effectively.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Software Maintenance Subscription |
| Unit Pricing | Pay-as-you-go | Professional Online Support (Application) |
Go-to-market motion2 records
Distribution channels10 records
Marketing channels7 records
Visiopharm product offering
Product offeringCore offering
Visiopharm develops and sells AI-driven precision pathology software for tissue image analysis in both research and clinical diagnostics. Its platform combines deep learning algorithms with 20 years of pathology expertise, offering core products (Discovery, Phenoplex, Insight for Diagnostics), add-on modules (Qualitopix, Tissuealign, Tissuearray), and a library of over 130 modular analysis APPs. The portfolio includes nine IVDR-cleared CE-IVD diagnostic algorithms for clinical decision support in cancer diagnostics.
Product overview
Visiopharm is a leading provider of AI-driven precision pathology software for research and diagnostics. The company offers a platform-plus-modules architecture combining core analysis engines (Discovery for research, Phenoplex for spatial biology, Insight for diagnostics) with specialized add-on modules (Qualitopix for IHC quality, Tissuealign for image alignment, Tissuearray for TMA de-arraying). The product portfolio includes over 130 modular analysis APPs in the APP Center, nine CE-IVD cleared diagnostic algorithms, and OEM scanner integrations (Hamamatsu NDP.Analyze, Grundium Ocus, Philips UltraFast). The platform is built on Visiopharm Engine (AI execution) and Author AI (custom APP development) technologies, enabling analysis across H&E, IHC, multiplex fluorescence, and RNA ISH modalities. Founded in 2002, the company serves over 750 customer accounts in more than 40 countries.
Differentiator
Problem solved
Functional benefit
Brands
- Discovery: AI-powered tissue image analysis software platform enabling researchers to train deep learning models for accurate and reproducible results.
- Phenoplex
- Insight
- Qualitopix
- Tissuealign
- Tissuearray
Products and services
- Discovery AI-powered tissue image analysis software for research applications. Enables pathologists and research scientists to train custom deep learning APPs for accurate and reproducible results without requiring programming expertise.
- Phenoplex Complete image analysis workflow for multiplexed spatial biology images. Enables spatial neighborhood analysis and cell phenotyping from multiplex fluorescence imaging data.
- Insight for Diagnostics Diagnostic decision support platform featuring IVDR-certified CE-IVD applications for clinical pathology workflows, providing diagnostic algorithms for biomarker assessment in cancer diagnostics.
- Qualitopix IHC staining consistency measurement and documentation tool that uses standardized analysis of next-generation reference materials to measure and document staining consistency in immunohistochemistry workflows.
- Tissuealign Image alignment module that aligns serial tissue sections at the cellular level for co-registration and co-localization analysis across different stains or biomarkers, enabling virtual multiplex staining workflows.
- Tissuearray Tissue micro-array de-arraying tool that automates the processing and analysis of tissue cores in TMAs for high-throughput tissue research.
- APP Center Library of over 130 modular analysis units (APPs) covering all tissue, stain, and modality types. Apps address specific analysis problems including cancer biomarkers, tumor microenvironment, spatial biology, and research applications, and can be used as building blocks for custom workflows.
- CE-IVD Diagnostic APPs Nine IVDR-cleared diagnostic algorithms providing diagnostic decision support for clinical pathology. Applications include ER, PR, Ki-67, HER2 Breast Cancer AI, Invasive Tumor Detection (PDS) APP, and other biomarker quantification tools for cancer diagnostics.
- Pharma Services Contract research services for pharmaceutical companies using Visiopharm's AI-powered image analysis platform, supporting drug discovery, biomarker analysis, and clinical trial research needs.
Quantifiable outcome
- Invasive tumor detection DICE score of 0.944 at Odense University Hospital, 0.81 at Pathology Diagnostics Jarutat, and 0.908 at University Medical Center Groningen (mean 0.888)
- +2 more outcomes
Companies that use Visiopharm
Customer profileNamed customers9 records
Segments4 records
Ideal customer profiles4 records
Visiopharm technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration6 records
AI capability12 records
Feature10 records
Visiopharm partnerships and signals
Strategic signalPartnerships
13 partnerships are on record, tiered flagship, core, major and minor.
- Hamamatsu PhotonicsflagshipVisiopharm is OEM for Hamamatsu's NDP.Analyze software. Hamamatsu is an authorized worldwide distributor of Visiopharm's image analysis and stereology software for research use only.
- Agilent TechnologiesflagshipGlobal life sciences company and authorized distributor of Visiopharm products, collaborating on digital pathology ecosystem and demonstrating integrated workflows at events like USCAP 2026.
- Akoya BiosciencescoreSpatial biology company and authorized distributor, with Visiopharm developing specific APPs for Akoya's Opal Multiplex IHC Detection Kits for tumor microenvironment analysis.
- ProsciacoreDigital pathology platform company and authorized distributor offering Visiopharm's AI-powered image analysis solutions to their customer base.
- Evident (Olympus)majorAuthorized distributor for Visiopharm's image analysis software in North America and Asia regions.
- ZEISSmajorAuthorized distributor for Visiopharm's image analysis software in Asia region.
- BYTE ConsultingminorAuthorized distributor for Visiopharm's image analysis solutions in China.
- Inter Instrument ASminorAuthorized distributor for Visiopharm's image analysis and stereology solutions in Norway.
- SellexminorAuthorized distributor for Visiopharm's image analysis and stereology software in Brazil.
- Jinan DanjierminorAuthorized distributor for Visiopharm's image analysis software in Asia.
- GrundiumcoreFinnish digital pathology scanner company acquired Visiopharm in May 2026 to create an integrated precision pathology platform combining digital slide scanning with AI-powered diagnostic applications. The acquisition builds on a pre-existing partnership and integration between the two firms.
- CND Life SciencesmajorCollaboration on NerValence AI-assisted digital pathology tool for analyzing skin biopsy samples in Parkinson's disease drug trials. Visiopharm provided AI analysis capabilities for the Syn-One biomarker services platform.
- PathAIcoreIntegration of Visiopharm's AI products into PathAI's AISight Image Management System, enhancing digital pathology workflows with algorithms for prostate, breast, and lung cancer diagnostics.
Scale indicators5 records
Recent moves6 records
Expansion highlights6 records
Visiopharm competitors and assessment
Company assessmentDirect peers
- Proscia: Digital pathology platform offering AI-powered image analysis for research and diagnostics; both channel partner and competitor. Serves biopharma and diagnostic labs with a cloud-native platform and Concentriq IMS - directly comparable use case and customer base.
- PathAI: AI pathology company building diagnostic and translational AI for cancer; integrated with Visiopharm's AI into AISight IMS. Operates in the same IVD/IHC diagnostic decision-support space with overlapping pharma and lab customers.
- Indica Labs: Developer of Halo image analysis platform for digital pathology, including multiplex phenotyping, IHC quantification, and AI-assisted diagnostics. Closely comparable to Visiopharm's Discovery and Phenoplex offerings for research and clinical workflows.
Broad incumbents
- Aperio (Leica Biosystems): Established digital pathology incumbent with whole-slide imaging scanners, image management, and AI algorithms, including recent Aperio GT IVD/Dx capabilities - competes for the same clinical pathology lab budget as Visiopharm's Insight platform.
- Philips Digital Pathology: Healthcare major's pathology business offers UltraFast scanners and Intellisite pathology solution with image management; supported as a Visiopharm integration target. Represents enterprise competition for hospital system deployments.
- Hamamatsu Photonics: Whole-slide scanner maker and OEM/distributor of Visiopharm (NDP.Analyze brand), NanoZoomer scanners are supported within Visiopharm workflows. Comparable in that Hamamatsu bundles image-analysis and scanner stack into enterprise pathology bids.
- Roche (uPath/Aperio combo): Pharma-major-affiliated digital pathology ecosystem targeting companion diagnostics and IVD labs. Competes for the largest reference labs and integrated healthcare systems that Visiopharm also seeks to win in cancer diagnostics.
Emerging players
- Akoya Biosciences: Spatial biology company offering Phenoptics and CODEX multiplex imaging, partnered with Visiopharm for co-developed APPs. Overlaps in multiplex tumor microenvironment workflows and competes for spatial biology translational pharma budgets.
- Ibex Medical Analytics: Clinical AI pathology company with CE-IVD-cleared algorithms for breast, prostate, and gastric cancer detection - direct rival to Visiopharm's IVDR algorithms in EU diagnostic labs seeking clinical decision support.
- QuPath: Open-source whole-slide image analysis platform widely adopted in academic pathology research. Represents low-cost alternative competing for research budgets that Visiopharm's Discovery platform targets.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Visiopharm social profiles
Digital presenceVisiopharm compliance and trust
Trust signalCompliance2 records
Visiopharm financial estimates
Financial estimateRevenue estimate
Valuation estimate
Visiopharm leadership team
Management profileNumber of profiles
Profiles3 records
Visiopharm funding detail
Funding detailFunding overview
Funding rounds3 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Visiopharm M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Visiopharm
What does Visiopharm do?
Visiopharm develops and sells AI-driven precision pathology software for tissue image analysis in both research and clinical diagnostics. Its platform combines deep learning algorithms with 20 years of pathology expertise, offering core products (Discovery, Phenoplex, Insight for Diagnostics), add-on modules (Qualitopix, Tissuealign, Tissuearray), and a library of over 130 modular analysis APPs. The portfolio includes nine IVDR-cleared CE-IVD diagnostic algorithms for clinical decision support in cancer diagnostics.
Is Visiopharm a public or private company?
Visiopharm is a private company. It is classified as corporate owned and is currently acquired.
When was Visiopharm founded?
Visiopharm was founded in 2002. It employs 11 to 50 people.
Where is Visiopharm based?
Visiopharm is headquartered in Hørsholm, Denmark, in the Europe region.
How does Visiopharm make money?
Four revenue lines are on record. Software Licenses are the primary driver. The others are software Maintenance Service, professional Services and training Services.
Who are Visiopharm's main competitors?
Direct peers on record are Proscia, PathAI and Indica Labs. Broad incumbents are Aperio (Leica Biosystems), Philips Digital Pathology, Hamamatsu Photonics and Roche (uPath/Aperio combo). Emerging players are Akoya Biosciences, Ibex Medical Analytics and QuPath.
Does Visiopharm have an API?
No public API is recorded for Visiopharm.
What industry is Visiopharm in?
Visiopharm's product category is Digital Pathology Software. Its primary akta.pro industry code is HLACANAG, SaMD – Imaging & Signal Analysis (AI/ML), with a secondary code of HDAAAEAH, Medical Imaging AI. Its NAICS code is 3391 and its SIC code is 2835.